Literature DB >> 8740728

Modification of the blood-brain barrier permeability by vinorelbine: effect of intracarotid infusion compared with intravenous infusion.

C Mouchard-Delmas1, B Gourdier, R Vistelle, M Wiczewski.   

Abstract

Brain levels of the antineoplastic compound, vinorelbine, and its effects on the permeability of the blood-brain barrier (BBB) were studied. Preliminary experiments were carried out to define the dose of 10 mg/kg and the delay of 3 h after infusion required to induce BBB disruption. Vinorelbine was infused by i.c. or i.v. infusion to anesthetized male Sprague-Dawley rats. BBB disruption was evaluated qualitatively by the presence in the infused hemisphere of i.v. administered Evans blue dye (2%) and vinorelbine intratissular levels were measured by HPLC. After an i.c. infusion, there is an important variability in the degree of extravasation of Evans blue albumin complex, which is correlated with vinorelbine levels (p < 0.01). The percent of dose in brain tissue is less than 1%. After an i.v. infusion, the parenchyma is globally affected as shown by the uniform faint bluish staining of the two hemispheres. Vinorelbine levels are homogenous and similar to levels of brains graded + 1 after an i.c. infusion. These results seem to indicate that an i.c. infusion induces localized BBB disruptions while the effect of an i.v. infusion is global and that the gain in tissue level after an i.c. infusion is low compared with i.v. infusion.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8740728     DOI: 10.1097/00001813-199602000-00011

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  4 in total

1.  Minimal residual disease after radical surgery in EGFR-mutant non-small cell lung cancer.

Authors:  Katsuhiro Masago; Yoshitsugu Horio; Shiro Fujita; Yasushi Yatabe
Journal:  Transl Lung Cancer Res       Date:  2019-12

2.  Astrocytes increase the functional expression of P-glycoprotein in an in vitro model of the blood-brain barrier.

Authors:  P J Gaillard; I C van der Sandt; L H Voorwinden; D Vu; J L Nielsen; A G de Boer; D D Breimer
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

3.  Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial.

Authors:  A M Omuro; J J Raizer; A Demopoulos; M G Malkin; L E Abrey
Journal:  J Neurooncol       Date:  2006-04-14       Impact factor: 4.130

4.  Safety and efficacy of vinorelbine in the treatment of non-small cell lung cancer.

Authors:  Bryan A Faller; Trailokya N Pandit
Journal:  Clin Med Insights Oncol       Date:  2011-05-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.